Dr Ali Taheri
Higher Degree by Research Candidate
School of Medicine
College of Health
| Year | Citation |
|---|---|
| 2025 | Taheri, A., Almasri, R., Wignall, A., Feltrin, F., Bremmell, K. E., Joyce, P., & Prestidge, C. A. (2025). Enteric coating enhances the Biopharmaceutical performance of a silica-lipid formulation of Abiraterone Acetate. Pharmaceutics, 17(10, article no. 1289), 1-12. |
| 2024 | Taheri, A., Almasri, R., Wignall, A., Schultz, H. B., Elz, A. S., Ariaee, A., . . . Prestidge, C. A. (2024). Enhancing the pharmacokinetics of abiraterone acetate through lipid-based formulations: addressing solubility and food effect challenges. Drug Delivery and Translational Research, online(11), 3770-3782. WoS2 Europe PMC1 |
| 2023 | Taheri, A., Bremmell, K. E., Joyce, P., & Prestidge, C. A. (2023). Battle of the milky way: lymphatic targeted drug delivery for pathogen eradication. Journal of Controlled Release, 363, 507-524. |
| 2023 | Tabarsi, P., Anjidani, N., Shahpari, R., Mardani, M., Sabzvari, A., Yazdani, B., . . . Barati, S. (2023). Evaluating the efficacy and safety of SpikoGen?, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial. CLINICAL MICROBIOLOGY AND INFECTION, 29(2), 215-220. WoS38 Europe PMC36 |
| 2022 | Tabarsi, P., Anjidani, N., Shahpari, R., Mardani, M., Sabzvari, A., Yazdani, B., . . . Barati, S. (2022). Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. CLINICAL MICROBIOLOGY AND INFECTION, 28(9), 1263-1271. WoS40 Europe PMC41 |
Courses I teach
- MATH 1065 Quantitative Methods in Health (2025)
- PHAR 2014 Dosage Form Design 1 (2025)
- PHAR 2014 Dosage Form Design 1 (2024)
- PHAR 2016 Dosage Form Design 2 (2024)
Connect With Me
External Profiles
